In the first two parts of BioWorld Insight's Innovation Analysis, we explored how although the creation and funding of new biotechs is not necessarily synonymous with the creation and funding of innovation, there are signs that venture capitalists are more willing to invest in innovative, early stage biotechs than they were five or six years ago.
Read More
At the 2011 meeting of the American Society of Clinical Oncology, MD Anderson professor Lee Ellis, in a talk about improving academic drug discovery, said that industrial researchers were unable to replicate half of the results published by their academic colleagues. (See BioWorld Today, June 8, 2011.) Read More
